Early Approvals Pave Smooth Biosimilar Path For Celltrion, Samsung
This article was originally published in PharmAsia News
Executive Summary
South Korea's Celltrion and Samsung Bioepis are competing hard to grab a slice of the burgeoning global biosimilar market. Celltrion’s Remicade biosimilar has already been widely launched and may only be a step away from entering the US, while Samsung Bioepis has received three regulatory approvals for its biosimilars. As the two continue to launch their products ahead of rivals, they are well on track to become core players in the global market in the coming years.